ChromaDex Q4 EPS $0.00 Beats $(0.03) Estimate, Sales $21.20M Beat $20.98M Estimate
Portfolio Pulse from Benzinga Newsdesk
ChromaDex (NASDAQ:CDXC) reported Q4 earnings of $0.00 per share, surpassing the $(0.03) estimate, marking a 105% increase from last year. Sales reached $21.20M, exceeding the $20.98M estimate, a 0.95% increase from the previous year.
March 06, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex reported a significant improvement in Q4 earnings and sales, beating estimates and showing year-over-year growth.
ChromaDex's positive earnings report, showing both a beat on EPS and sales estimates, indicates strong financial health and operational efficiency. This outperformance, especially in comparison to last year's losses, is likely to instill investor confidence and could lead to a short-term uptick in CDXC's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100